Skip to main content

Table 4 Troxacitabine and gemcitabine combination studies in the human pancreatic AsPc-1 xenograft tumor model.

From: Synergistic activity of troxacitabine (Troxatyl™) and gemcitabine in pancreatic cancer

Group

Dose and Schedule

Tumor Volumes mm3 Day 45

% T/Ca

Pvalues

Compared with saline control group

Pvalues

Compared with gemcitabine treated group

Control (Saline)

5 mL/kg IV

q3d × 4

804

-

  

Troxacitabine

1 mg/kg IV

q3d × 4

324

41%

P = 0.0126

 

Troxacitabine

5 mg/kg IV

q3d × 4

90

12%

P < 0.001

 

Gemcitabine

80 mg/kg IP

q3d × 4

631

79%

P = 0.31

 

Troxacitabine + Gemcitabine

1 mg/kg IV +

80 mg/kg IP

q3d × 4

215

27%

P = 0.0021

P = 0.0074

  1. a Tumor measurements were taken twice weekly. Drug efficacy was assessed at Day 45, time at which animals from the control group had to be sacrificed due to tumor burden, as the percentage of T/C, determined by calculating RVT as: T/C% = 100 × (mean RTV of treated group)/(mean RVT of control group).
  2. Female SCID mice were inoculated SC with 5 × 106 AsPc-1 cells (Day 0). Treatment with troxacitabine and/or gemcitabine was started 14 days after tumor cell inoculation, once the mice had developed palpable tumors.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us